Moderna On Track to Finish Enrollment for Phase 3 COVID-19 Vaccine Study Before Oct.
One of the companies working on a vaccine for the coronavirus says it’s on track to finish enrollment for a phase three study before October.
Moderna also said it plans to sell the vaccine at below $40 per dose for most customers.
The company is teaming up with Michigan-based Henry Ford Health System in its trial.
Henry Ford tells us they’ve just given the first doses to some people in Michigan as part of that trial.
All drug companies are being closely watched to see what they plan to charge for COVID-19 treatments.
Biotech company Gilead revealed in June that its Remdesivir drug would cost more than $500 a vial for people with private health insurance.